Interview 16 Oct 2017 Meet the Former Banker at the Helm of Denmark’s Healthcare Giant, Novo Holdings Kasim Kutay has ridden the biotech investment wave. First, he helped build Morgan Stanley’s European healthcare group, then did the same at Moelis & Co and now he heads Novo Holdings, the majority shareholder of Danish household biotech names NovoZymes and Novo Nordisk. I asked him about the company’s healthcare investment strategy and his CEO […] October 16, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 11 Oct 2017 Are Precision Medicine and Digital Health Here Yet? I connected online with digital health, genomics and precision medicine expert Vishal Gulati to talk about how the advent of data-based healthcare will reshape how patients are treated. A partner at VC firm Draper Esprit, Vishal Gulati focuses his investments on genomics and digital health. Or, as he describes it, on “companies that create value for patients using the […] October 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 9 Oct 2017 The Woman Developing the Next Generation of Cancer Immunotherapy Özlem Türeci discusses the future of individualized cancer therapy and her journey to become an entrepreneur and take science to patients. As a trained physician and immunologist, Dr. Özlem Türeci has led her own research group with Prof. Ugur Sahin at the University of Mainz, Germany, since 2000. But academic research was not enough for her, […] October 9, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 4 Oct 2017 4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […] October 4, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 28 Sep 2017 What are Alphabodies and How Do They Drug the Undruggable? Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […] September 28, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 28 Sep 2017 Ethical Drug Development can Start with Charity Investors: A Conversation As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity investors. In August, a story emerged that Novartis CEO Joe Jimenez not only responded to a patient’s letter but met with him soon thereafter to […] September 28, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 27 Sep 2017 What’s this Top Swiss VC Up To These Days? General Partner Tells All Philip caught up with Markus Hosang to find out which companies the VC is keeping an eye on after its next round of fundraising. General Partner, Markus Hosang has a strong background in pharma and VC, which serves him well when searching through the bustling biotech industry in Europe. BioMed Partners is a very active […] September 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 25 Sep 2017 Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model Onno van de Stolpe founded Galapagos nearly 20 years ago and still is CEO of this European biotech success story. I caught up with him for the full story. It was when he was studying at the agricultural university in Wageningen, The Netherlands, when “I got fascinated by molecular biology, and the biotech industry in […] September 25, 2017 - 10 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 20 Sep 2017 A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive Derek Jones is at the helm of Babraham Bioscience Technologies. I caught up with him to talk about strategies for biotech startups. Confusion is common when it comes to navigating the various organizing entities of Babraham, a life science campus just a few kilometers southeast of Cambridge. It’s famously home to a number of standout […] September 20, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 18 Sep 2017 David Chiswell: “We are getting close to the best way of making antibodies” We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […] September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 14 Sep 2017 Inside the Lab Building a Stem Cell Gun to Heal Skin Thomas Bold, CEO of RenovaCare, shares the story of how his team developed a futuristic stem cell gun to heal burns and wounds. Inside the building that used to be home to Berlin’s Tempelhof airport, whose abandoned runways are regularly visited by picnickers and skaters, an American and a German company are collaborating on the […] September 14, 2017 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 11 Sep 2017 Meet the CEO of Europe’s Largest & Most Fiercely Independent Biotech Jan van de Winkel co-founded Genmab as CSO and then became CEO to develop the antibody company into a fully independent commercial enterprise. Here’s his strategy. Since its foundation in 1999, Genmab has become Europe’s largest biotech and a proud parent of a half billion-euro drug, daratumumab. Co-founding CSO Jan van de Winkel played a […] September 11, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email